© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of May 27, 2016, the consensus forecast amongst 22 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on May 02, 2016. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 21 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,400, with a high estimate of 2,000 and a low estimate of 1,190. The median estimate is equal to the last price of 1,400. View Full Financials
Historical dividend information is not available for Kalbe Farma Tbk PT. View Full Financials
|Div growth (TTM)||--|
On Apr 29, 2016, Kalbe Farma Tbk PT reported 1st quarter 2016 earnings of 12.02 per share.
The next earnings announcement is expected on Jul 29, 2016. View Full Interim Financials
|Average growth rate||+6.22 %|
Kalbe Farma Tbk PT reported annual 2015 earnings of 42.76 per share on Feb 26, 2016. View Full Annual Financials
|Average growth rate||+8.10 %|
PT. Kalbe Farma Tbk. had 1st quarter 2016 revenues of 4.550bn. This missed the 4.637bn consensus estimate of the 2 analysts following the company. This was 7.14% above the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+1.86 %|
PT. Kalbe Farma Tbk. had revenues for the full year 2015 of 17.887bn. This was 2.99% above the prior year's results. View Full Annual Financials
|Average growth rate||+13.46 %|